Evidence map›Paper›PMID 40038676›Full record

ArticleReproductive biology and endocrinology : RB&E2025

ViLR: a novel virtual long read method for breakpoint identification and direct SNP haplotyping in de novo PGT-SR carriers without a proband.

Jiangyang Xue, Min Xie, Jie Cai, Kai Kang, Mengnan Gu, Mai Li, Haiyue Shi, Xin Zhang, Lingyin Kong, Bo Liang and 3 more

Abstract read
In one paragraph

Article in Reproductive biology and endocrinology : RB&E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jiangyang Xue *The Central Laboratory of Birth Defects Prevention and Control, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, Zhejiang, 315012, China.
Min Xie *The Central Laboratory of Birth Defects Prevention and Control, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, Zhejiang, 315012, China.
Jie CaiCenter for Reproductive Medicine, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, Zhejiang, 315012, China.
Kai KangBasecare Medical Device Co., Ltd, Suzhou, Jiangsu, 215028, China.
Mengnan GuBasecare Medical Device Co., Ltd, Suzhou, Jiangsu, 215028, China.
Mai LiCenter for Reproductive Medicine, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, Zhejiang, 315012, China.
Haiyue ShiCenter for Reproductive Medicine, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, Zhejiang, 315012, China.
Xin ZhangBasecare Medical Device Co., Ltd, Suzhou, Jiangsu, 215028, China.
Lingyin KongBasecare Medical Device Co., Ltd, Suzhou, Jiangsu, 215028, China.
Bo LiangState Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic and Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.
Liming ZhouCenter for Reproductive Medicine, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, Zhejiang, 315012, China.
Changshui ChenNingbo Key Laboratory for the Prevention and Treatment of Embryogenic Diseases, The Affiliated Women and Children's Hospital of Ningbo University, 339 Liuting Street, Haishu District, Ningbo, Zhejiang, 315012, China. chencs@139.com.
Haibo LiThe Central Laboratory of Birth Defects Prevention and Control, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, Zhejiang, 315012, China. lihaibo-775@163.com.

Funding

Innovation Project of Distinguished Medical Team in Ningbo 2022020405Key Technology Breakthrough Program of 'Ningbo Sci-Tech Innovation YONGJIANG 2035' 2024Z221Medical and Health Project of Zhejiang province 2022KY1157Ningbo Medical and HealthBrand Discipline PPXK2024-06Ningbo science and technology project 2023Z178the Social Development Public Welfare Foundation of Ningbo 2022S035
6 · The paper itself

Abstract

backgroundDespite the gradual application of third-generation long read sequencing (LRS) or reference embryo establishment to preimplantation genetic testing for structural rearrangement (PGT-SR) without familial involvement, there are still limitations to their extensive clinical application yet. This study developed a novel virtual NGS-based long read method (ViLR) and preliminarily evaluated its clinical feasibility of breakpoint characterization and direct SNP haplotyping for de novo chromosomal structural rearrangements (CSR).

methodsA total of 10 families with de novo CSR risk were enrolled in this study for ViLR analysis. In contrast to LRS, ViLR is a virtual long read solution that used the same barcoded labeling and assembly of different long gDNAs differently barcoded. Notably, ViLR could generate an average fragment length of over 30 Kb, with an N50 block size of up to 16 Mb in a single assay, allowing to achieve accurate breakpoint mapping and direct carrier's haplotyping. An approximately 2 Mbp region flanking upstream and downstream of each breakpoint was selected for informative SNP collection. Embryo haplotype determination was based on the established carriers' haplotypes after whole genome amplification and sequencing. To confirm PGT-SR results, we performed prenatal genetic diagnosis.

resultsThis study achieved an average mapping rate of 99.5%, > 90% coverage depth (> 10X), an average number of effective barcode (> 5 kb length) counts of 11,000,000 and an average fragment length of 40 kb, which generated sufficient informative SNPs for breakpoint characterization and haplotype phasing. ViLR analysis of 10 de novo PGT-SR carriers precisely identified breakpoints and haplotypes. Seven families obtained 18 euploid embryos, in which 10 were euploid/normal embryos, 7 were euploid/balanced carrier embryos, and the remaining one unknown was due to homologous recombination of the breakpoint region. Prenatal genetic diagnosis was performed for four women, and the outcomes coincided with the results from embryo PGT-SR. At the time of writing this paper, four healthy babies had been delivered uneventfully.

conclusionHere, we demonstrated the clinical potential of ViLR as a novel solution for breakpoint identification and direct SNP haplotyping in de novo PGT-SR families without proband involvement. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Chromosome BreakpointsGenetic TestingHaplotypesPolymorphism, Single NucleotidePreimplantation DiagnosisAdultFemaleHeterozygoteHigh-Throughput Nucleotide SequencingHumansMalePregnancyBreakpoint identificationDe novoDirect SNP haplotypingPreimplantation genetic testing for structural rearrangement (PGT-SR)Virtual NGS-based long read method (ViLR)

Identifiers

PMID40038676
PMCPMC11881346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.